Investor Overview Press Releases December 3, 2021 Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine November 18, 2021 Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021 November 3, 2021 Aclaris Therapeutics to Participate in Upcoming Investor Conferences View all » Events Dec 7, 202110:00 AM EST Aclaris Therapeutics, Inc. Virtual R&D Day Nov 22, 202110:00 AM EST Aclaris Therapeutics, Inc. at Piper Sandler 33rd Annual Virtual Healthcare Conference Nov 18, 20213:00 AM EST Aclaris Therapeutics, Inc. at Jefferies London Healthcare Conference View all » Feature Presentation Aclaris Therapeutics Company Overview - November 2021 Derivative Stockholder Action Notice of Pendency and Proposed Settlement of Stockholder Derivative Action Stipulation and Agreement of Settlement Settlement Hearing Information
December 3, 2021 Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine
Nov 22, 202110:00 AM EST Aclaris Therapeutics, Inc. at Piper Sandler 33rd Annual Virtual Healthcare Conference
